NeuroSense Therapeutics Ltd.
NRSN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $7 | $6 | $3 |
| G&A Expenses | $4 | $5 | $7 | $3 |
| SG&A Expenses | $4 | $5 | $7 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | -$0 | $0 |
| Operating Expenses | $10 | $12 | $13 | $6 |
| Operating Income | -$10 | -$12 | -$14 | -$6 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | $2 | $1 | $2 |
| Pre-Tax Income | -$10 | -$11 | -$12 | -$4 |
| Tax Expense | $0 | $0 | -$1 | $0 |
| Net Income | -$10 | -$10 | -$12 | -$4 |
| % Margin | – | – | – | – |
| EPS | -0.55 | -0.83 | -1.07 | -0.23 |
| % Growth | 33.7% | 22.4% | -365.2% | – |
| EPS Diluted | -0.55 | -0.83 | -1.07 | -0.23 |
| Weighted Avg Shares Out | 19 | 14 | 12 | 11 |
| Weighted Avg Shares Out Dil | 19 | 14 | 12 | 11 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$10 | -$10 | -$12 | -$3 |
| % Margin | – | – | – | – |